US Consumer Health Industry In 2023: With Supply Chain Concerns Constant, Challenges Loom Larger
Executive Summary
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight begins reporting from those talks with outlook for supply chain nd production disruptions and prevalence of COVID-19 and other widespread viruses.
You may also be interested in...
To Prevent Shortages, US FDA Wants Notices From Drug Firms On Spikes In Demand
Demand-related shortages are a relatively new problem, but FDA maintains its tools can prevent or end them.
US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
Biden-Xi Bali Meet Reopens US-China Cooperation, Looks Positive For Health Players
A meeting between the heads of the world's two largest economies potentially opens the door for health cooperation, a rare positive sign amid worsening economic decoupling, accelerating diversification away from China and the need for multinationals to modify localization strategy.